查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1696278

日本糖尿病數位治療市場 - 2025 至 2033 年

Japan Digital Therapeutics for Diabetes Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年日本糖尿病數位治療市場規模達到 5,659 萬美元，預計到 2033 年將達到 1.3644 億美元，在 2025-2033 年預測期內的複合年成長率為 10.4%。

糖尿病的數位療法是指基於證據的、軟體驅動的干涉措施，旨在管理和治療糖尿病，主要著重於改善健康結果和透過科技管理病情。這些干預措施使用行動應用程式、穿戴式裝置和連網平台等數位工具，為糖尿病患者提供個人化的治療和支援。數位療法利用從患者裝置（如血糖儀、穿戴式裝置或行動應用程式）收集的即時資料來持續監測血糖水平、體力活動、飲食和藥物依從性。

市場動態：

促進因素與約束因素

日本糖尿病盛行率上升推動糖尿病數位治療市場成長

根據國際糖尿病聯盟（IDF）統計，日本有1,100萬成年人患有糖尿病。糖尿病的高盛行率與沉重的經濟負擔有關，這可歸因於生活方式的改變和壽命的延長。日本是世界上老化程度最高的國家之一（29% 的人口為 65 歲或以上），這顯著增加了糖尿病病例的數量。老年人更容易患第2型糖尿病，對慢性病管理的需求更高。

日本目前的糖尿病管理模式嚴重依賴頻繁就醫、注射胰島素和身體檢查。無論對於醫療保健系統還是患者來說，這都是昂貴且耗時的。隨著糖尿病患者數量的增加，傳統的方法已不足以應對日益成長的患者數量。行動應用程式、穿戴式裝置（如連續血糖監測儀）和人工智慧驅動平台等數位解決方案可提供遠端監控、個人化回饋和即時管理。這些技術有助於減少頻繁就診的需要，並允許患者更好地在家中追蹤自己的健康狀況。

隨著越來越多的人被診斷出患有糖尿病，對數位化糖尿病管理等經濟高效、可擴展且方便的解決方案的需求也日益增加。人口老化、高昂的醫療成本以及政府對數位健康科技的支持，共同構成了日本糖尿病管理市場的一個主要趨勢。利用數位健康科技預防和治療糖尿病是糖尿病管理的最新趨勢。

資料隱私和安全問題阻礙了日本糖尿病數位療法市場的成長

日本製定了《個人資訊保護法》（APPI）等嚴格的資料保護法，對個人和健康資料的儲存和共享設定了高標準。數位治療公司必須遵守這些法規，以保護患者的敏感健康資訊。滿足這些法規的複雜性增加了數位健康公司的開發和營運成本。

APPI 規定獲取個人資料的公司需要獲得患者的明確同意，這可能會延遲日本新的數位治療解決方案的開發和部署。公司必須確保資料安全存儲，並立即報告違規行為，這帶來了合規性挑戰。

由於擔心隱私和濫用，許多日本患者可能不願意與數位健康平台分享他們的健康資料。這種不信任可能會限制數位療法的採用，尤其是當患者不確定他們的資料將如何被使用、共享或儲存時。由於數位治療解決方案連接到雲端並依賴網際網路進行即時資料共享，資料外洩或駭客攻擊的風險增加。安全漏洞可能會暴露患者的醫療和個人資料，損害數位治療提供者的聲譽並導致法律後果。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段

第 3 章：動態

  • 影響因素
    • 驅動程式
      • 日本糖尿病盛行率上升
      • 不斷進步的技術
    • 限制
      • 資料隱私和安全問題
      • 監管挑戰
    • 機會
      • 糖尿病數位治療中的人工智慧
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • 新興創業公司和關鍵創新者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 日本監管和報銷狀況
  • 波特五力分析
  • 供應鏈分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：糖尿病數位治療市場（依產品類型）

  • 軟體解決方案
    • 行動應用程式
    • 基於 Web 的解決方案
  • 硬體解決方案
    • 穿戴式裝置
    • 連續血糖監測儀
    • 其他

第 6 章：糖尿病數位治療市場（按應用）

  • 1 型糖尿病
  • 2 型糖尿病
  • 糖尿病前期

第 7 章：糖尿病數位治療市場（以最終用戶分類）

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他

第 8 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第9章：公司簡介

  • Welldoc, Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Omada Health Inc.
  • Glooko, Inc.
  • Azumio Inc.
  • Abbott Laboratories
  • Life Log Technology, Inc.
  • Dexcom, Inc.
  • Health2Sync
  • iHealth Labs Inc.
  • Medtronic plc

第 10 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 11 章：附錄

簡介目錄
Product Code: HCIT9374

The Japan digital therapeutics for diabetes market size reached US$ 56.59 million in 2024 and is expected to reach US$ 136.44 million by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033.

Digital therapeutics for diabetes refers to evidence-based, software-driven interventions designed to manage and treat diabetes, primarily focusing on improving health outcomes and managing the condition through technology. These interventions use digital tools, such as mobile apps, wearable devices and connected platforms, to provide personalized treatments and support for individuals with diabetes. Digital therapeutics leverage real-time data collected from patients' devices (such as glucose meters, wearables or mobile apps) to provide continuous monitoring of blood glucose levels, physical activity, diet and medication adherence.

Market Dynamics: Drivers & Restraints

The rising prevalence of diabetes in Japan driving the digital therapeutics for diabetes market growth

According to the International Diabetes Federation (IDF), 11 million adults in Japan have diabetes. The high prevalence of diabetes is associated with a significant economic burden and can be attributed to lifestyle changes and increased longevity. Japan's aging population, which is one of the oldest in the world (29% of the population is 65 years or older), significantly increases the number of diabetes cases. Older adults are more susceptible to Type 2 diabetes, leading to higher demands for chronic disease management.

The current diabetes management model in Japan is heavily reliant on frequent doctor visits, insulin injections and physical check-ups. This is costly and time-consuming, both for the healthcare system and for patients. As the number of diabetes patients rises, the traditional approach is proving insufficient to handle the increasing volume. Digital solutions like mobile apps, wearable devices (such as continuous glucose monitors) and AI-driven platforms offer remote monitoring, personalized feedback and real-time management. These technologies help reduce the need for frequent visits and allow patients to better track their health from home.

As more people are diagnosed with diabetes, the need for cost-effective, scalable and convenient solutions like digital diabetes management increases. The combination of an aging population, high healthcare costs and government backing for digital health technologies makes a key trend in Japan's diabetes management market. Using digital health technology to prevent and treat diabetes is the latest trend in diabetes management.

Data privacy and security concerns hampering the growth of Japan digital therapeutics for diabetes market

Japan has stringent data protection laws under the Act on the Protection of Personal Information (APPI), which sets high standards for the storage and sharing of personal and health data. Digital therapeutics companies must comply with these regulations to protect patients' sensitive health information. The complexity of meeting these regulations adds to the development and operational costs for digital health companies.

The APPI mandates that companies obtaining personal data need explicit consent from patients, which can delay the development and deployment of new digital therapeutic solutions in Japan. Companies must ensure data is securely stored and breaches are immediately reported, creating compliance challenges.

Many Japanese patients may be hesitant to share their health data with digital health platforms due to concerns about privacy and misuse. This mistrust can limit the adoption of digital therapeutics, especially if patients feel unsure about how their data will be used, shared or stored. As digital therapeutics solutions are connected to the cloud and rely on the internet for real-time data sharing, the risk of data breaches or hacking increases. A breach in security could expose patients' medical and personal data, damaging the reputation of the digital therapeutics provider and leading to legal ramifications.

Segment Analysis

The Japan digital therapeutics for diabetes market is segmented based on product type, application and end-user.

Product Type:

The software solutions in the product type segment are expected to dominate the Japan digital therapeutics for diabetes market with the highest market share

Software solutions including mobile apps and digital platforms can provide personalized diabetes management by using real-time data and AI-driven algorithms to deliver customized treatment recommendations. These solutions allow patients to track blood glucose levels, diet, physical activity and medication adherence daily, offering individualized feedback.

For instance, in March 2023, Health2Sync announced its latest version of the Health2Sync App integrates insulin data from Mallya Cap, the connected device dedicated to insulin pens developed by Biocorp and marketed in Japan by Novo Nordisk. This partnership realizes the first data integration of its kind and is expected to help patients on insulin treatment manage their health by capturing multiple data points, including insulin injection logs.

Software solutions, particularly mobile applications, are highly accessible and can be used on smartphones or tablets, allowing patients to manage their diabetes from anywhere. This convenience is especially beneficial for the aging population in Japan, many of whom are managing diabetes and prefer digital tools that offer self-monitoring and remote consultation features.

Competitive Landscape

The major Japan players in the digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, Life Log Technology, Inc., Dexcom, Inc., Health2Sync, iHealth Labs Inc. and Medtronic plc among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan digital therapeutics for diabetes market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures and 158 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes in Japan
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy and Security Concerns
      • 3.1.2.2. Regulatory Challenges
    • 3.1.3. Opportunity
      • 3.1.3.1. Artificial Intelligence in Diabetes Digital Therapeutics
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Japan Regulatory and Reimbursement Landscape
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics

5. Digital Therapeutics for Diabetes Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Software Solutions*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Mobile Apps
    • 5.2.4. Web-Based Solutions
  • 5.3. Hardware Solutions
    • 5.3.1. Wearable Devices
    • 5.3.2. Continuous Glucose Monitors
    • 5.3.3. Others

6. Digital Therapeutics for Diabetes Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Type-1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type-2 Diabetes
  • 6.4. Pre-Diabetes

7. Digital Therapeutics for Diabetes Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. Welldoc, Inc.*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue's
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Omada Health Inc.
  • 9.3. Glooko, Inc.
  • 9.4. Azumio Inc.
  • 9.5. Abbott Laboratories
  • 9.6. Life Log Technology, Inc.
  • 9.7. Dexcom, Inc.
  • 9.8. Health2Sync
  • 9.9. iHealth Labs Inc.
  • 9.10. Medtronic plc

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us